That could benefit Eli Lilly, whose Zepbound helps treat obesity, and its stock climbed 4.9%. The threat of higher inflation ...

U.S. stocks are rising to trim their losses in what’s set to be one of their worst weeks of the year. The S&P 500 climbed 0.7 ...

Shares in Danish drug maker Novo Nordisk NOVO, known for its blockbuster drugs Ozempic and Wegovy, fell as much as 28% on ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

Shares of Novo Nordisk plunged by as much as 24% on Friday, marking a significant setback for the Danish pharmaceutical giant ...

A lawsuit forced the FDA to reassess its ruling on the availability of tirzepatide, the active ingredient in the popular drugs Mounjaro and Zepbound from Eli Lilly. As a result, the agency also told ...

Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug ...

Novo Nordisk (NVO) stock is tumbling 21% today after individuals who received the company’s experimental weight-loss drug ...

Novo Nordisk announced underwhelming results in a trial for its obesity drug CagriSema, causing its market value to drop by $125 billion. The trial showed 22.7% weight loss, below the expected 25%.

Novo Nordisk's CagriSema, a combination drug for weight loss, matches Lilly's Zepbound in late-stage trial, but doesn't surpass it. Stock falls 19% on news.